Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iopofosine I 131 - Cellectar Biosciences

Next Previous
Drug Profile

Iopofosine I 131 - Cellectar Biosciences

Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 1404 I-131; CLR-131; HOT; I-131-CLR1404; NM-404

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Phospholipid ethers; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdomyosarcoma; Neuroblastoma; Osteosarcoma; Multiple myeloma; Ewing's sarcoma; Glioma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Phase I/II Non-small cell lung cancer
  • Phase I Brain cancer; Glioma; Lymphoma; Solid tumours
  • No development reported Head and neck cancer

Most Recent Events

  • 27 Oct 2025 Phase I development is ongoing in Brain cancer (In adolescents, In children, Second-line therapy or greater, In adults) in Canada, Australia, USA (IV) (NCT03478462)
  • 27 Oct 2025 Phase I development is ongoing in Lymphoma (In adolescents, In children, Second-line therapy or greater, In adults) in Canada, Australia, USA (IV) (NCT03478462)
  • 27 Oct 2025 Phase I development is ongoing in Solid tumours (In adolescents, In children, Second-line therapy or greater, In adults) in Canada, Australia, USA (IV) (NCT03478462)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top